B+
Bull case
20%
Probability
Target price
$2.75
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
EVO
Evotec SEBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$1.80
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.10
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-12
Recent news sentiment (30D)
-0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+70.0
Score
AI commentary
News flow is mixed. Evotec's directly retrieved August 13 company release confirmed weak H1 profitability and sharply reduced guidance, while its September 9 company release documented the JST-018 Phase 1 transition and the two government contracts' combined potential value of up to $123.9 million [#PR-2026-08-13] [#PR-2026-09-09]. The $1.73 anchor indicates that the guidance shock has not fully reversed. Available analyst revisions remain cautious, but the packet lacks a reliable analyst count and comprehensive post-H1 revision coverage. Social, options, short-interest and employee-sentiment coverage are unavailable; their zero values denote missing evidence rather than neutrality.
RankAlpha Sentiment Codex - 2026-09-12
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-11-05event9M results test the reduced outlookMedium impact
The November 5 reporting checkpoint should show whether stronger customer activity is beginning to convert into revenue. Evotec's August 13 results confirmed H1 revenue of €300.1 million, adjusted EBITDA of negative €42.7 million, and FY2026 guidance for revenue of €570–610 million and adjusted EBITDA of negative €70–105 million [#PR-2026-08-13].
2026-12-31catalystQ4 conversion of improved commercial activityHigh impact
D&PD net sales excluding strategic partnerships grew approximately 28% year over year in H1, but management cautioned that partnership timing, complexity and revenue ramp-up remain variable. Evidence of conversion into reported revenue would support stabilization; another delay would reinforce weak visibility [#PR-2026-08-13].
2027-09-30catalystJust–Evotec platform validationHigh impact
The September initiation of the JST-018 Phase 1 study demonstrated Just–Evotec Biologics' ability to take a government antibody program through preclinical and process development, regulatory submission, and clinical-material manufacturing. The two previously announced government contracts have combined potential value of up to $123.9 million, although incremental economics and future milestone timing were not disclosed [#PR-2026-09-09].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-12 • Updated nightlySource: Internal modelMethodology